Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HepeX-B versus hepatitis B immune globulin after liver transplantation for hepatitis B
2004-000501-21Phase 2Completed
- Sponsor
- XTL Biopharmaceuticals Ltd.
- Start
- Feb 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of XTL-001 in hepatitis B (HBV) (2 arms), sponsored by XTL Biopharmaceuticals Ltd. Primary endpoint: Proportion of patients without virologic breakthrough. Started Feb 2005; status: completed.
02
Drugs
XTL-001
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2004-000501-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000501-21.